PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.

This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA.  In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of bamlanivimab alone and bamlanivimab plus etesevimab combination for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for […]